Pfizer/Pharmacia Merger: Tidbits From The SEC Filings
COX-2 co-marketing amendment: Pfizer would gain majority control over Pfizer/Pharmacia COX-2 co-marketing executive committee should Pharmacia terminate the merger agreement under certain conditions, Pfizer's Aug. 14 S-4 merger filing with the Securities & Exchange Commission states. Pfizer would name three members to the five-person committee should Pharmacia end the deal; Pfizer is currently represented by two members. The company would also be able to appoint a chairperson to "any or all" of the six subcommittees of the executive committee under the amended agreement. The merger breakup fee is $1.6 bil...
You may also be interested in...
Pfizer's $11 bil. premium above Pharmacia's recent stock market valuation is a figure calculated from the estimated operating savings in the companies' proposed stock-for-stock transaction
Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients
Pfizer is preparing an NDA supplement for Neurontin that could allow open marketing of gabapentin for neuropathic pain indications.